{"id":38836,"date":"2020-08-28T07:17:25","date_gmt":"2020-08-28T07:17:25","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=38836"},"modified":"2020-08-28T09:22:37","modified_gmt":"2020-08-28T09:22:37","slug":"insight-network-to-study-monoclonal-antibody-ly-cov555-for-covid-19","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/38836","title":{"rendered":"INSIGHT network to study monoclonal antibodies for COVID-19 including LY-CoV555"},"content":{"rendered":"
\n

<\/span>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n

\n

On 4 August 2020 the US NIH announced a new study of a monoclonal antibody LY-CoV555\u00a0<\/span>as a treatment for COVID-19, in a study run by the INSIGHT network (responsible for the SMART and START studies).<\/strong><\/p>\n<\/div>\n

\n

The ACTIV-3 study will use an adaptive two-stage phase 3 design that can be adapted to test additional experimental treatments at either stage 1 or stage 2.<\/span><\/p>\n<\/div>\n

\n

If a treatment appears to be safe and effective in the initial stage, the investigational therapeutic proceeds to stage 2 testing, with more participants.<\/span><\/p>\n<\/div>\n

\n

LY-CoV555 was isolated from an adult who recovered from COVID-19 and was discovered by Abcellera Biologics in collaboration with NIAIDs vaccine research centre and developed by Eli Lilly.<\/span><\/p>\n<\/div>\n

\n

Stage 1 will randomise approximately 300 volunteers who have been hospitalised with mild to moderate COVID-19 with fewer than 13 days of symptoms to either active treatment or placebo. \u00a0An additional 700 participants will be enrolled if the compound progresses to stage 2.<\/span>Standard of care for all participants will also include remdesivir.<\/p>\n

The use of a shared placebo group means that as new compounds are added, the chances for new participants to receive an active antibody treatment also increases.<\/p>\n<\/div>\n

\n

Reference<\/span><\/p>\n<\/div>\n

\n

NIH press release. NIH launches clinical trial to test antibody treatment in hospitalized COVID-19 patients. (4 August 2020).
\n<\/span>https:\/\/www.nih.gov\/news-events\/news-releases\/nih-launches-clinical-trial-test-antibody-treatment-hospitalized-covid-19-patients<\/a><\/p>\n

This article was originally posted on 5 August 2020.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Simon Collins, HIV i-Base On 4 August 2020 the US NIH announced a new study of a monoclonal antibody LY-CoV555\u00a0as a treatment for COVID-19, in a study run by the INSIGHT network (responsible for the SMART and START studies). The …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[283,278],"tags":[],"class_list":["post-38836","post","type-post","status-publish","format-standard","hentry","category-covid-19-investigational-drugs","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38836","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=38836"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/38836\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=38836"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=38836"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=38836"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}